Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 225 | 2023 | 1790 | 12.650 |
Why?
|
Smoking | 190 | 2017 | 1135 | 8.860 |
Why?
|
Polymorphism, Genetic | 83 | 2014 | 896 | 4.030 |
Why?
|
Polymorphism, Single Nucleotide | 93 | 2023 | 2932 | 3.870 |
Why?
|
DNA Repair | 65 | 2012 | 627 | 3.850 |
Why?
|
Mexican Americans | 37 | 2019 | 207 | 3.730 |
Why?
|
Case-Control Studies | 226 | 2019 | 3629 | 3.540 |
Why?
|
Carcinoma, Squamous Cell | 76 | 2016 | 874 | 3.530 |
Why?
|
Genetic Predisposition to Disease | 143 | 2023 | 3471 | 3.460 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 42 | 2016 | 383 | 3.360 |
Why?
|
Head and Neck Neoplasms | 68 | 2015 | 692 | 3.310 |
Why?
|
Mutagens | 38 | 2007 | 84 | 3.170 |
Why?
|
Lymphocytes | 58 | 2011 | 440 | 2.490 |
Why?
|
Risk Factors | 216 | 2019 | 11006 | 2.130 |
Why?
|
Receptors, Nicotinic | 19 | 2016 | 160 | 2.040 |
Why?
|
Bleomycin | 39 | 2008 | 156 | 2.010 |
Why?
|
Neoplasms | 45 | 2015 | 3006 | 2.010 |
Why?
|
Chromosome Aberrations | 37 | 2015 | 625 | 1.950 |
Why?
|
Middle Aged | 313 | 2019 | 29237 | 1.950 |
Why?
|
Chromosomes, Human, Pair 15 | 14 | 2016 | 163 | 1.850 |
Why?
|
Genetic Variation | 33 | 2019 | 1610 | 1.840 |
Why?
|
Genome-Wide Association Study | 42 | 2023 | 1869 | 1.810 |
Why?
|
Aged | 218 | 2018 | 21619 | 1.600 |
Why?
|
Male | 367 | 2022 | 65619 | 1.580 |
Why?
|
Adenocarcinoma | 31 | 2017 | 1074 | 1.570 |
Why?
|
Genotype | 99 | 2017 | 2804 | 1.540 |
Why?
|
Female | 362 | 2021 | 71345 | 1.510 |
Why?
|
DNA Damage | 30 | 2012 | 542 | 1.470 |
Why?
|
Adolescent Behavior | 10 | 2019 | 178 | 1.430 |
Why?
|
Humans | 487 | 2023 | 133290 | 1.420 |
Why?
|
Carcinogens | 25 | 2010 | 159 | 1.390 |
Why?
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 26 | 2007 | 36 | 1.370 |
Why?
|
Odds Ratio | 70 | 2016 | 1337 | 1.340 |
Why?
|
Biomarkers, Tumor | 24 | 2016 | 1705 | 1.260 |
Why?
|
Molecular Epidemiology | 15 | 2012 | 162 | 1.200 |
Why?
|
DNA-Binding Proteins | 32 | 2022 | 2157 | 1.110 |
Why?
|
Urinary Bladder Neoplasms | 20 | 2007 | 548 | 1.100 |
Why?
|
Chromosomes, Human, Pair 5 | 13 | 2019 | 123 | 1.100 |
Why?
|
Neoplasms, Second Primary | 15 | 2012 | 163 | 1.090 |
Why?
|
Insulin-Like Growth Factor I | 11 | 2006 | 353 | 1.070 |
Why?
|
Diet | 22 | 2013 | 1196 | 1.050 |
Why?
|
Mouth Neoplasms | 17 | 2008 | 114 | 1.010 |
Why?
|
Risk | 48 | 2016 | 833 | 0.980 |
Why?
|
Carcinoma | 9 | 2010 | 320 | 0.960 |
Why?
|
Epidemiology | 2 | 2015 | 10 | 0.940 |
Why?
|
Mutagenicity Tests | 15 | 2007 | 35 | 0.940 |
Why?
|
Tobacco Use Disorder | 10 | 2015 | 96 | 0.900 |
Why?
|
Professional Competence | 2 | 2015 | 99 | 0.870 |
Why?
|
Attitude to Health | 4 | 2014 | 261 | 0.860 |
Why?
|
Prostatic Neoplasms | 20 | 2015 | 1626 | 0.860 |
Why?
|
Smoking Cessation | 16 | 2016 | 208 | 0.850 |
Why?
|
Logistic Models | 38 | 2014 | 1903 | 0.850 |
Why?
|
Tobacco Smoke Pollution | 6 | 2012 | 94 | 0.840 |
Why?
|
Adult | 151 | 2018 | 31851 | 0.830 |
Why?
|
Inflammation | 12 | 2015 | 1599 | 0.830 |
Why?
|
Small Cell Lung Carcinoma | 6 | 2016 | 37 | 0.810 |
Why?
|
Texas | 54 | 2014 | 3677 | 0.800 |
Why?
|
Nerve Tissue Proteins | 14 | 2016 | 1158 | 0.780 |
Why?
|
Alleles | 27 | 2016 | 1703 | 0.780 |
Why?
|
Telomerase | 9 | 2019 | 179 | 0.720 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 9 | 2006 | 57 | 0.710 |
Why?
|
Alcohol Drinking | 26 | 2019 | 387 | 0.710 |
Why?
|
Genes, p53 | 8 | 2006 | 234 | 0.700 |
Why?
|
Models, Statistical | 7 | 2013 | 505 | 0.690 |
Why?
|
Aged, 80 and over | 56 | 2018 | 7184 | 0.660 |
Why?
|
Rhinitis, Allergic, Seasonal | 5 | 2013 | 25 | 0.650 |
Why?
|
Motor Activity | 3 | 2012 | 537 | 0.640 |
Why?
|
Pharyngeal Neoplasms | 10 | 2008 | 32 | 0.630 |
Why?
|
Risk Assessment | 27 | 2022 | 3665 | 0.620 |
Why?
|
Hormone Replacement Therapy | 4 | 2012 | 211 | 0.610 |
Why?
|
DNA Adducts | 11 | 2010 | 82 | 0.600 |
Why?
|
Linkage Disequilibrium | 16 | 2013 | 334 | 0.600 |
Why?
|
Chromosomes, Human, Pair 3 | 5 | 2008 | 100 | 0.600 |
Why?
|
Family Health | 10 | 2017 | 267 | 0.600 |
Why?
|
DNA, Neoplasm | 17 | 2011 | 317 | 0.590 |
Why?
|
Multivariate Analysis | 22 | 2015 | 1486 | 0.590 |
Why?
|
Glutathione Transferase | 10 | 2008 | 163 | 0.580 |
Why?
|
BRCA2 Protein | 2 | 2015 | 53 | 0.580 |
Why?
|
Cocarcinogenesis | 6 | 2011 | 22 | 0.570 |
Why?
|
Acculturation | 6 | 2014 | 69 | 0.570 |
Why?
|
Sex Factors | 27 | 2014 | 1374 | 0.560 |
Why?
|
Laryngeal Neoplasms | 9 | 2007 | 104 | 0.560 |
Why?
|
Cell Cycle | 5 | 2011 | 628 | 0.550 |
Why?
|
Pain | 5 | 2013 | 478 | 0.550 |
Why?
|
Somatomedins | 3 | 2002 | 37 | 0.540 |
Why?
|
Gene Frequency | 27 | 2015 | 777 | 0.530 |
Why?
|
Disease Susceptibility | 26 | 2005 | 317 | 0.510 |
Why?
|
Isotretinoin | 6 | 2012 | 24 | 0.510 |
Why?
|
Prognosis | 27 | 2016 | 5065 | 0.510 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 2 | 2006 | 35 | 0.490 |
Why?
|
Neoplasm Staging | 19 | 2016 | 1399 | 0.490 |
Why?
|
Polymerase Chain Reaction | 33 | 2016 | 1632 | 0.480 |
Why?
|
Promoter Regions, Genetic | 10 | 2011 | 1413 | 0.480 |
Why?
|
Genetic Markers | 11 | 2013 | 630 | 0.470 |
Why?
|
Peroxidase | 6 | 2007 | 73 | 0.460 |
Why?
|
Cohort Studies | 20 | 2016 | 5174 | 0.460 |
Why?
|
Confidence Intervals | 19 | 2014 | 301 | 0.450 |
Why?
|
Social Perception | 3 | 2009 | 59 | 0.450 |
Why?
|
Folic Acid | 6 | 2013 | 299 | 0.440 |
Why?
|
Health Behavior | 5 | 2011 | 400 | 0.440 |
Why?
|
Germ-Line Mutation | 2 | 2016 | 370 | 0.440 |
Why?
|
Age Factors | 31 | 2014 | 2971 | 0.430 |
Why?
|
Cotinine | 3 | 2013 | 27 | 0.430 |
Why?
|
Dust | 3 | 2006 | 19 | 0.420 |
Why?
|
Neoplasms, Multiple Primary | 7 | 1994 | 72 | 0.410 |
Why?
|
Haplotypes | 14 | 2014 | 561 | 0.400 |
Why?
|
DNA Helicases | 8 | 2005 | 251 | 0.400 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 7 | 2018 | 630 | 0.400 |
Why?
|
Salivary Gland Neoplasms | 6 | 1990 | 67 | 0.400 |
Why?
|
Sensation | 1 | 2012 | 59 | 0.400 |
Why?
|
Interleukin-2 Receptor beta Subunit | 1 | 2012 | 6 | 0.390 |
Why?
|
In Situ Hybridization, Fluorescence | 12 | 2010 | 790 | 0.390 |
Why?
|
Membrane Proteins | 6 | 2019 | 1607 | 0.390 |
Why?
|
Exploratory Behavior | 1 | 2012 | 55 | 0.380 |
Why?
|
Proteins | 9 | 2015 | 1087 | 0.380 |
Why?
|
Precancerous Conditions | 8 | 2008 | 288 | 0.370 |
Why?
|
Genome, Human | 10 | 2015 | 1347 | 0.370 |
Why?
|
Exome | 2 | 2016 | 1067 | 0.370 |
Why?
|
United States | 41 | 2015 | 11633 | 0.370 |
Why?
|
Health Promotion | 2 | 2014 | 399 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 183 | 0.370 |
Why?
|
Reproductive History | 1 | 2011 | 11 | 0.360 |
Why?
|
Wood | 2 | 2005 | 11 | 0.360 |
Why?
|
Digoxin | 1 | 2011 | 44 | 0.360 |
Why?
|
Adolescent | 42 | 2019 | 20480 | 0.360 |
Why?
|
Proportional Hazards Models | 15 | 2014 | 1475 | 0.350 |
Why?
|
Cytochrome P-450 CYP2E1 | 3 | 2005 | 9 | 0.340 |
Why?
|
Phenotype | 16 | 2016 | 4518 | 0.340 |
Why?
|
Regression Analysis | 15 | 2011 | 832 | 0.330 |
Why?
|
Predictive Value of Tests | 15 | 2011 | 2294 | 0.330 |
Why?
|
Occupational Exposure | 7 | 2012 | 140 | 0.330 |
Why?
|
Prospective Studies | 20 | 2014 | 6629 | 0.330 |
Why?
|
ROC Curve | 7 | 2014 | 613 | 0.330 |
Why?
|
Nuclear Proteins | 9 | 2011 | 1328 | 0.330 |
Why?
|
Insulin-Like Growth Factor II | 4 | 2003 | 45 | 0.320 |
Why?
|
Antibiotics, Antineoplastic | 9 | 2006 | 137 | 0.320 |
Why?
|
Environmental Exposure | 8 | 2012 | 244 | 0.320 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 7 | 2013 | 71 | 0.320 |
Why?
|
Receptors, Dopamine D2 | 2 | 2000 | 47 | 0.320 |
Why?
|
Life Style | 4 | 2011 | 453 | 0.320 |
Why?
|
Family | 3 | 2012 | 588 | 0.310 |
Why?
|
Chromatids | 9 | 2006 | 41 | 0.310 |
Why?
|
Social Environment | 2 | 2011 | 123 | 0.310 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2008 | 90 | 0.300 |
Why?
|
Smoking Prevention | 5 | 2014 | 37 | 0.300 |
Why?
|
Mosaicism | 3 | 2016 | 245 | 0.300 |
Why?
|
Epidemiologic Methods | 9 | 2014 | 110 | 0.300 |
Why?
|
Telomere | 3 | 2006 | 229 | 0.300 |
Why?
|
Incidence | 21 | 2014 | 3381 | 0.300 |
Why?
|
Exons | 14 | 2008 | 833 | 0.300 |
Why?
|
Cytokinesis | 4 | 2014 | 26 | 0.300 |
Why?
|
Transcription Factors | 10 | 2007 | 2700 | 0.300 |
Why?
|
Age of Onset | 9 | 2016 | 636 | 0.300 |
Why?
|
Tumor Suppressor Proteins | 8 | 2012 | 508 | 0.290 |
Why?
|
Ultraviolet Rays | 8 | 2005 | 217 | 0.290 |
Why?
|
Cytokines | 3 | 2013 | 1396 | 0.290 |
Why?
|
Area Under Curve | 5 | 2014 | 331 | 0.290 |
Why?
|
Breast Neoplasms | 9 | 2015 | 2762 | 0.290 |
Why?
|
Cytochrome P-450 Enzyme System | 4 | 2004 | 140 | 0.290 |
Why?
|
Cell Cycle Proteins | 7 | 2010 | 695 | 0.290 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2008 | 38 | 0.290 |
Why?
|
Cisplatin | 2 | 2010 | 284 | 0.290 |
Why?
|
Surveys and Questionnaires | 26 | 2014 | 3983 | 0.290 |
Why?
|
Respiratory Tract Neoplasms | 4 | 1998 | 14 | 0.280 |
Why?
|
Body Mass Index | 9 | 2013 | 1703 | 0.280 |
Why?
|
Gene Dosage | 2 | 2008 | 456 | 0.280 |
Why?
|
Nitrosamines | 5 | 2013 | 21 | 0.280 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2011 | 793 | 0.280 |
Why?
|
Germ Cells | 1 | 2008 | 202 | 0.280 |
Why?
|
DNA Breaks | 1 | 2007 | 26 | 0.280 |
Why?
|
Chromosomes, Human, Pair 9 | 6 | 2006 | 114 | 0.270 |
Why?
|
Alkylating Agents | 1 | 2007 | 10 | 0.270 |
Why?
|
Anticarcinogenic Agents | 6 | 1999 | 54 | 0.270 |
Why?
|
Plants, Toxic | 6 | 1999 | 11 | 0.270 |
Why?
|
Phytoestrogens | 3 | 2005 | 16 | 0.270 |
Why?
|
Analysis of Variance | 8 | 2014 | 1047 | 0.270 |
Why?
|
Pilot Projects | 21 | 2013 | 1484 | 0.270 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 44 | 0.260 |
Why?
|
Radiation Pneumonitis | 2 | 2010 | 12 | 0.260 |
Why?
|
Chi-Square Distribution | 10 | 2014 | 603 | 0.260 |
Why?
|
Asthma | 4 | 2008 | 806 | 0.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1352 | 0.260 |
Why?
|
Genes, Tumor Suppressor | 8 | 2008 | 224 | 0.250 |
Why?
|
Skin Neoplasms | 11 | 2005 | 905 | 0.250 |
Why?
|
Follow-Up Studies | 12 | 2016 | 5481 | 0.250 |
Why?
|
Chromosomes, Human, Pair 6 | 3 | 2012 | 145 | 0.250 |
Why?
|
Ferredoxin-NADP Reductase | 4 | 2013 | 11 | 0.250 |
Why?
|
DNA Primers | 15 | 2015 | 671 | 0.250 |
Why?
|
Gamma Rays | 10 | 2007 | 54 | 0.240 |
Why?
|
Amifostine | 1 | 2005 | 14 | 0.240 |
Why?
|
Motion Pictures | 2 | 2019 | 8 | 0.240 |
Why?
|
Imitative Behavior | 2 | 2019 | 6 | 0.240 |
Why?
|
Air Pollutants, Occupational | 1 | 2005 | 18 | 0.240 |
Why?
|
Chromosomes, Human | 5 | 2014 | 137 | 0.240 |
Why?
|
Radiation-Protective Agents | 1 | 2005 | 20 | 0.240 |
Why?
|
Genetic Association Studies | 9 | 2018 | 842 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2012 | 1192 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2008 | 1730 | 0.230 |
Why?
|
Pulmonary Emphysema | 2 | 2010 | 95 | 0.230 |
Why?
|
Neoplasms, Radiation-Induced | 5 | 2005 | 86 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 8 | 2014 | 1133 | 0.230 |
Why?
|
Gene-Environment Interaction | 3 | 2016 | 133 | 0.230 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 8 | 2010 | 866 | 0.230 |
Why?
|
Epoxide Hydrolases | 2 | 2002 | 39 | 0.230 |
Why?
|
Chromosomes, Human, Pair 13 | 3 | 1999 | 51 | 0.220 |
Why?
|
Genetics, Population | 6 | 2014 | 198 | 0.220 |
Why?
|
Chemoprevention | 4 | 2006 | 58 | 0.220 |
Why?
|
Neoplasm Proteins | 5 | 2014 | 717 | 0.220 |
Why?
|
Biomedical Research | 4 | 2015 | 555 | 0.220 |
Why?
|
Cells, Cultured | 13 | 2007 | 3171 | 0.220 |
Why?
|
Survival Analysis | 9 | 2011 | 1596 | 0.210 |
Why?
|
Carcinogens, Environmental | 2 | 2015 | 15 | 0.210 |
Why?
|
Peer Group | 5 | 2019 | 121 | 0.210 |
Why?
|
Epidemiologic Studies | 5 | 2013 | 47 | 0.210 |
Why?
|
Antioxidants | 5 | 2008 | 373 | 0.210 |
Why?
|
Base Sequence | 16 | 2015 | 3169 | 0.210 |
Why?
|
Folic Acid Deficiency | 1 | 2003 | 55 | 0.210 |
Why?
|
Survival Rate | 9 | 2013 | 2201 | 0.210 |
Why?
|
Pancreatic Neoplasms | 1 | 2009 | 737 | 0.210 |
Why?
|
Reference Values | 11 | 2012 | 746 | 0.210 |
Why?
|
Mass Screening | 6 | 2022 | 831 | 0.210 |
Why?
|
Age Distribution | 7 | 2007 | 442 | 0.210 |
Why?
|
Chromosome Breakage | 8 | 2006 | 167 | 0.200 |
Why?
|
Tobacco, Smokeless | 4 | 2015 | 14 | 0.200 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 4 | 2005 | 28 | 0.200 |
Why?
|
Carcinoma, Small Cell | 6 | 2010 | 50 | 0.200 |
Why?
|
Body Height | 2 | 2021 | 231 | 0.200 |
Why?
|
Polymorphism, Restriction Fragment Length | 11 | 2007 | 153 | 0.200 |
Why?
|
Gene Expression Regulation, Neoplastic | 11 | 2014 | 2114 | 0.200 |
Why?
|
Erythroplasia | 1 | 2002 | 2 | 0.200 |
Why?
|
Leukoplakia, Oral | 1 | 2002 | 4 | 0.200 |
Why?
|
Prevalence | 11 | 2015 | 2647 | 0.200 |
Why?
|
Gene Deletion | 4 | 1998 | 809 | 0.190 |
Why?
|
Ascorbic Acid | 4 | 2001 | 82 | 0.190 |
Why?
|
DNA Glycosylases | 3 | 2010 | 33 | 0.190 |
Why?
|
Sensitivity and Specificity | 11 | 2010 | 2162 | 0.190 |
Why?
|
Micronucleus Tests | 4 | 2012 | 7 | 0.190 |
Why?
|
Quantitative Trait Loci | 3 | 2022 | 319 | 0.190 |
Why?
|
Chromosomes | 4 | 2002 | 165 | 0.190 |
Why?
|
Fatigue | 2 | 2013 | 203 | 0.190 |
Why?
|
Socioeconomic Factors | 10 | 2015 | 914 | 0.190 |
Why?
|
Pseudogenes | 2 | 1999 | 53 | 0.180 |
Why?
|
Comet Assay | 5 | 2010 | 13 | 0.180 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 1999 | 64 | 0.180 |
Why?
|
Digestive System Neoplasms | 2 | 1998 | 14 | 0.180 |
Why?
|
Aging | 4 | 2016 | 1298 | 0.180 |
Why?
|
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 3 | 2005 | 22 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2012 | 1311 | 0.180 |
Why?
|
Tumor Cells, Cultured | 9 | 2011 | 1101 | 0.180 |
Why?
|
Chromosomes, Human, X | 2 | 2016 | 161 | 0.180 |
Why?
|
Bayes Theorem | 5 | 2015 | 314 | 0.180 |
Why?
|
Parents | 2 | 2007 | 1059 | 0.180 |
Why?
|
Radiation Injuries | 3 | 2010 | 164 | 0.170 |
Why?
|
Isothiocyanates | 1 | 2000 | 14 | 0.170 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2001 | 645 | 0.170 |
Why?
|
Educational Status | 3 | 2014 | 293 | 0.170 |
Why?
|
False Positive Reactions | 3 | 2012 | 147 | 0.170 |
Why?
|
Software | 3 | 2012 | 733 | 0.170 |
Why?
|
Cross-Sectional Studies | 8 | 2016 | 3733 | 0.170 |
Why?
|
Europe | 6 | 2021 | 384 | 0.170 |
Why?
|
Leptin | 2 | 2001 | 225 | 0.170 |
Why?
|
Cytochrome P-450 CYP2A6 | 3 | 2014 | 14 | 0.170 |
Why?
|
Glypicans | 2 | 2010 | 41 | 0.170 |
Why?
|
Multicenter Studies as Topic | 2 | 1998 | 289 | 0.160 |
Why?
|
Genetic Loci | 4 | 2014 | 366 | 0.160 |
Why?
|
Dietary Fats | 2 | 1998 | 301 | 0.160 |
Why?
|
DNA Methylation | 6 | 2016 | 1144 | 0.160 |
Why?
|
Genomic Instability | 3 | 2012 | 243 | 0.160 |
Why?
|
Research Design | 4 | 2008 | 757 | 0.160 |
Why?
|
Interviews as Topic | 7 | 2013 | 417 | 0.160 |
Why?
|
Body Composition | 1 | 2002 | 564 | 0.160 |
Why?
|
Carcinoma, Large Cell | 3 | 2016 | 10 | 0.160 |
Why?
|
Sister Chromatid Exchange | 5 | 2007 | 19 | 0.160 |
Why?
|
Insurance, Health, Reimbursement | 2 | 1997 | 39 | 0.160 |
Why?
|
Carcinoma, Hepatocellular | 4 | 2013 | 995 | 0.160 |
Why?
|
Time Factors | 12 | 2015 | 6562 | 0.150 |
Why?
|
Glycine Hydroxymethyltransferase | 3 | 2011 | 6 | 0.150 |
Why?
|
Placebos | 4 | 2011 | 240 | 0.150 |
Why?
|
Obesity | 5 | 2013 | 2405 | 0.150 |
Why?
|
Lung Diseases | 3 | 2013 | 398 | 0.150 |
Why?
|
4-Nitroquinoline-1-oxide | 3 | 1999 | 8 | 0.150 |
Why?
|
Mutagenesis | 2 | 1997 | 352 | 0.150 |
Why?
|
Database Management Systems | 2 | 1988 | 32 | 0.150 |
Why?
|
Pharmacogenetics | 3 | 2010 | 196 | 0.150 |
Why?
|
Asbestos | 2 | 2012 | 13 | 0.150 |
Why?
|
In Vitro Techniques | 5 | 2007 | 992 | 0.150 |
Why?
|
Antiporters | 1 | 1998 | 36 | 0.140 |
Why?
|
Signal Transduction | 5 | 2015 | 4881 | 0.140 |
Why?
|
Trace Elements | 2 | 2008 | 29 | 0.140 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 412 | 0.140 |
Why?
|
Mexico | 5 | 2008 | 190 | 0.140 |
Why?
|
Probability | 5 | 2019 | 335 | 0.140 |
Why?
|
Health Maintenance Organizations | 1 | 1997 | 24 | 0.140 |
Why?
|
Trinucleotide Repeats | 2 | 2016 | 108 | 0.140 |
Why?
|
Cyclin D1 | 4 | 2008 | 123 | 0.140 |
Why?
|
Liver Neoplasms | 4 | 2013 | 1406 | 0.140 |
Why?
|
Databases, Factual | 4 | 2014 | 1243 | 0.140 |
Why?
|
Treatment Outcome | 12 | 2014 | 12957 | 0.140 |
Why?
|
Minority Groups | 4 | 2004 | 255 | 0.140 |
Why?
|
Multigene Family | 3 | 2013 | 323 | 0.140 |
Why?
|
Sex Distribution | 4 | 2012 | 328 | 0.140 |
Why?
|
Nicotine | 5 | 2012 | 147 | 0.140 |
Why?
|
Chromosome Mapping | 7 | 2017 | 1124 | 0.140 |
Why?
|
Child | 19 | 2015 | 25678 | 0.140 |
Why?
|
Isoflavones | 3 | 2005 | 46 | 0.130 |
Why?
|
Fathers | 2 | 1989 | 73 | 0.130 |
Why?
|
Codon | 7 | 2006 | 108 | 0.130 |
Why?
|
Colorectal Neoplasms | 4 | 2015 | 649 | 0.130 |
Why?
|
Public Health | 3 | 2015 | 286 | 0.130 |
Why?
|
Seasons | 2 | 1996 | 329 | 0.130 |
Why?
|
Preventive Health Services | 1 | 1997 | 61 | 0.130 |
Why?
|
Disease-Free Survival | 7 | 2012 | 971 | 0.130 |
Why?
|
Chromosomal Instability | 2 | 2008 | 63 | 0.130 |
Why?
|
X Chromosome Inactivation | 1 | 2016 | 64 | 0.130 |
Why?
|
Melanoma | 7 | 2005 | 974 | 0.130 |
Why?
|
Huntingtin Protein | 1 | 2016 | 65 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1998 | 197 | 0.130 |
Why?
|
Wnt Signaling Pathway | 2 | 2014 | 205 | 0.120 |
Why?
|
Checkpoint Kinase 2 | 2 | 2014 | 38 | 0.120 |
Why?
|
Exercise | 2 | 2012 | 877 | 0.120 |
Why?
|
Parent-Child Relations | 2 | 2015 | 253 | 0.120 |
Why?
|
5' Untranslated Regions | 2 | 2006 | 61 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2012 | 359 | 0.120 |
Why?
|
Patient Education as Topic | 2 | 2012 | 461 | 0.120 |
Why?
|
Family Conflict | 1 | 2015 | 18 | 0.120 |
Why?
|
Antineoplastic Agents | 4 | 2012 | 1844 | 0.120 |
Why?
|
Proline | 1 | 1995 | 80 | 0.120 |
Why?
|
International Agencies | 1 | 2015 | 31 | 0.120 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2003 | 266 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 891 | 0.120 |
Why?
|
fas Receptor | 2 | 2006 | 50 | 0.120 |
Why?
|
Huntington Disease | 1 | 2016 | 145 | 0.120 |
Why?
|
Loss of Heterozygosity | 4 | 2007 | 135 | 0.120 |
Why?
|
Thymidylate Synthase | 2 | 2004 | 23 | 0.120 |
Why?
|
Publications | 1 | 2015 | 36 | 0.120 |
Why?
|
Social Class | 3 | 2008 | 204 | 0.120 |
Why?
|
Young Adult | 6 | 2018 | 9872 | 0.120 |
Why?
|
Tumor Protein p73 | 4 | 2011 | 31 | 0.120 |
Why?
|
Reproducibility of Results | 7 | 2016 | 3057 | 0.110 |
Why?
|
Apoptosis | 5 | 2011 | 1931 | 0.110 |
Why?
|
Ethanol | 3 | 1996 | 171 | 0.110 |
Why?
|
Algorithms | 6 | 2012 | 1726 | 0.110 |
Why?
|
Family Practice | 1 | 1995 | 93 | 0.110 |
Why?
|
Tobacco Industry | 1 | 2014 | 8 | 0.110 |
Why?
|
HLA-D Antigens | 1 | 2014 | 14 | 0.110 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 19 | 0.110 |
Why?
|
Tobacco Products | 2 | 2012 | 72 | 0.110 |
Why?
|
Mass Media | 1 | 2014 | 28 | 0.110 |
Why?
|
Risk-Taking | 2 | 2014 | 105 | 0.110 |
Why?
|
Carrier Proteins | 3 | 2001 | 1060 | 0.110 |
Why?
|
Interleukin-8 | 2 | 2012 | 220 | 0.110 |
Why?
|
Homozygote | 9 | 2010 | 559 | 0.110 |
Why?
|
Residence Characteristics | 4 | 2012 | 292 | 0.110 |
Why?
|
Chromosomes, Human, Pair 4 | 3 | 2002 | 59 | 0.110 |
Why?
|
Carotenoids | 2 | 2005 | 79 | 0.110 |
Why?
|
Depression | 2 | 2013 | 1344 | 0.110 |
Why?
|
beta Carotene | 4 | 2005 | 41 | 0.110 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 2 | 2008 | 160 | 0.110 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 6 | 2005 | 25 | 0.110 |
Why?
|
Selection, Genetic | 1 | 2014 | 168 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 2 | 2008 | 251 | 0.110 |
Why?
|
Pain Measurement | 3 | 2009 | 362 | 0.110 |
Why?
|
Matrix Metalloproteinase 1 | 2 | 2005 | 25 | 0.110 |
Why?
|
Endonucleases | 3 | 2002 | 54 | 0.110 |
Why?
|
Interdisciplinary Communication | 1 | 2014 | 134 | 0.110 |
Why?
|
Leukemia | 3 | 1994 | 377 | 0.110 |
Why?
|
Mutation | 7 | 2018 | 6267 | 0.110 |
Why?
|
Iron, Dietary | 1 | 2013 | 18 | 0.100 |
Why?
|
Receptors, Cytokine | 1 | 2013 | 69 | 0.100 |
Why?
|
Cytochrome P-450 CYP2B6 | 1 | 2013 | 16 | 0.100 |
Why?
|
Chemoradiotherapy | 1 | 2014 | 129 | 0.100 |
Why?
|
Meat | 1 | 2013 | 48 | 0.100 |
Why?
|
Wnt Proteins | 1 | 2014 | 223 | 0.100 |
Why?
|
Synaptosomal-Associated Protein 25 | 1 | 2012 | 12 | 0.100 |
Why?
|
Drug-Seeking Behavior | 1 | 2012 | 7 | 0.100 |
Why?
|
Body Image | 1 | 2013 | 41 | 0.100 |
Why?
|
Cell Line | 8 | 2004 | 2842 | 0.100 |
Why?
|
Receptor, Cannabinoid, CB1 | 1 | 2012 | 30 | 0.100 |
Why?
|
Heme | 1 | 2013 | 54 | 0.100 |
Why?
|
Plasmids | 2 | 2007 | 525 | 0.100 |
Why?
|
Lipase | 1 | 2013 | 98 | 0.100 |
Why?
|
Nervous System Neoplasms | 2 | 1989 | 12 | 0.100 |
Why?
|
Tryptophan Hydroxylase | 1 | 2012 | 34 | 0.100 |
Why?
|
Medical Oncology | 2 | 2013 | 243 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2014 | 262 | 0.100 |
Why?
|
Biological Evolution | 2 | 2012 | 256 | 0.100 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2012 | 56 | 0.100 |
Why?
|
Phytosterols | 2 | 2005 | 29 | 0.100 |
Why?
|
Tretinoin | 3 | 2005 | 118 | 0.100 |
Why?
|
Inhalation Exposure | 1 | 2012 | 41 | 0.100 |
Why?
|
Dietary Supplements | 2 | 2008 | 498 | 0.100 |
Why?
|
Selenium | 3 | 2007 | 20 | 0.100 |
Why?
|
Thyroid Neoplasms | 2 | 2001 | 256 | 0.100 |
Why?
|
Gene Regulatory Networks | 2 | 2012 | 396 | 0.100 |
Why?
|
Databases, Genetic | 2 | 2012 | 500 | 0.100 |
Why?
|
Testicular Neoplasms | 4 | 1987 | 135 | 0.100 |
Why?
|
Research Report | 1 | 2012 | 79 | 0.100 |
Why?
|
Rad52 DNA Repair and Recombination Protein | 1 | 2011 | 6 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2015 | 383 | 0.100 |
Why?
|
Progestins | 1 | 2012 | 52 | 0.090 |
Why?
|
DNA | 7 | 2006 | 1663 | 0.090 |
Why?
|
Disease Progression | 9 | 2011 | 2231 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2011 | 514 | 0.090 |
Why?
|
Statistics as Topic | 4 | 2012 | 262 | 0.090 |
Why?
|
Transcription Factor AP-2 | 1 | 2011 | 23 | 0.090 |
Why?
|
Airway Remodeling | 1 | 2011 | 21 | 0.090 |
Why?
|
Phytohemagglutinins | 3 | 2007 | 13 | 0.090 |
Why?
|
Analgesics | 2 | 2009 | 134 | 0.090 |
Why?
|
Data Interpretation, Statistical | 4 | 2006 | 240 | 0.090 |
Why?
|
Oxidoreductases Acting on CH-NH Group Donors | 2 | 2001 | 27 | 0.090 |
Why?
|
Kidney Neoplasms | 2 | 2008 | 460 | 0.090 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2011 | 33 | 0.090 |
Why?
|
Needs Assessment | 1 | 2013 | 184 | 0.090 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2011 | 95 | 0.090 |
Why?
|
Activin Receptors, Type I | 1 | 2011 | 36 | 0.090 |
Why?
|
Epigenesis, Genetic | 2 | 2014 | 774 | 0.090 |
Why?
|
Matched-Pair Analysis | 3 | 2010 | 33 | 0.090 |
Why?
|
CD30 Ligand | 1 | 2011 | 2 | 0.090 |
Why?
|
Interleukin-10 | 1 | 2012 | 191 | 0.090 |
Why?
|
Receptors, Chemokine | 1 | 2011 | 49 | 0.090 |
Why?
|
Menarche | 1 | 2011 | 37 | 0.090 |
Why?
|
Uterine Cervical Diseases | 1 | 1991 | 6 | 0.090 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 466 | 0.090 |
Why?
|
Health Surveys | 2 | 2009 | 258 | 0.090 |
Why?
|
Eating | 1 | 2013 | 387 | 0.090 |
Why?
|
Feeding Behavior | 3 | 2013 | 726 | 0.090 |
Why?
|
Registries | 5 | 2003 | 1551 | 0.090 |
Why?
|
Models, Theoretical | 2 | 2012 | 398 | 0.090 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2010 | 30 | 0.090 |
Why?
|
Genotyping Techniques | 3 | 2019 | 111 | 0.090 |
Why?
|
Endometrial Neoplasms | 1 | 2011 | 113 | 0.090 |
Why?
|
Tandem Repeat Sequences | 1 | 2010 | 38 | 0.080 |
Why?
|
Statistics, Nonparametric | 4 | 2008 | 454 | 0.080 |
Why?
|
Micronuclei, Chromosome-Defective | 2 | 2008 | 9 | 0.080 |
Why?
|
Likelihood Functions | 2 | 2013 | 121 | 0.080 |
Why?
|
Copper | 2 | 2007 | 68 | 0.080 |
Why?
|
Anxiety | 2 | 2015 | 989 | 0.080 |
Why?
|
Data Collection | 3 | 2013 | 396 | 0.080 |
Why?
|
Molecular Sequence Data | 6 | 2015 | 3970 | 0.080 |
Why?
|
Carcinogenesis | 1 | 2013 | 361 | 0.080 |
Why?
|
Health Education | 1 | 1992 | 228 | 0.080 |
Why?
|
3' Untranslated Regions | 3 | 2005 | 182 | 0.080 |
Why?
|
Vitamin B Complex | 2 | 2013 | 43 | 0.080 |
Why?
|
Electric Power Supplies | 1 | 1989 | 19 | 0.080 |
Why?
|
Metagenome | 1 | 2011 | 158 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2010 | 78 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1996 | 807 | 0.080 |
Why?
|
Human Genome Project | 1 | 2009 | 56 | 0.080 |
Why?
|
Longitudinal Studies | 3 | 2015 | 1480 | 0.080 |
Why?
|
Gene Amplification | 2 | 2007 | 247 | 0.080 |
Why?
|
Zinc | 2 | 2007 | 141 | 0.080 |
Why?
|
SEER Program | 2 | 2001 | 222 | 0.080 |
Why?
|
RNA, Messenger | 8 | 2010 | 2896 | 0.080 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 2 | 2006 | 21 | 0.080 |
Why?
|
Esophagitis | 2 | 2010 | 41 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2014 | 17380 | 0.080 |
Why?
|
Estrogens | 1 | 2012 | 521 | 0.080 |
Why?
|
Disease | 1 | 2010 | 134 | 0.080 |
Why?
|
Occupations | 2 | 1987 | 22 | 0.080 |
Why?
|
Patient Selection | 2 | 2007 | 731 | 0.080 |
Why?
|
Gene Expression Profiling | 2 | 2013 | 1911 | 0.080 |
Why?
|
Isoenzymes | 2 | 2003 | 232 | 0.080 |
Why?
|
Interleukin-6 | 2 | 2008 | 452 | 0.080 |
Why?
|
Estrogens, Non-Steroidal | 2 | 1999 | 19 | 0.080 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 11 | 0.080 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2010 | 270 | 0.080 |
Why?
|
DNA Replication | 1 | 2011 | 362 | 0.080 |
Why?
|
Tocopherols | 1 | 2008 | 8 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2010 | 229 | 0.080 |
Why?
|
Genes, Reporter | 4 | 2011 | 394 | 0.080 |
Why?
|
Glutathione S-Transferase pi | 2 | 2006 | 27 | 0.080 |
Why?
|
Evolution, Molecular | 3 | 2014 | 710 | 0.080 |
Why?
|
Consumer Health Information | 1 | 2009 | 30 | 0.080 |
Why?
|
Drug Utilization | 1 | 2009 | 166 | 0.080 |
Why?
|
Image Cytometry | 1 | 2008 | 12 | 0.070 |
Why?
|
Emigration and Immigration | 2 | 2007 | 82 | 0.070 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2008 | 71 | 0.070 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2008 | 22 | 0.070 |
Why?
|
Boron | 1 | 2008 | 3 | 0.070 |
Why?
|
Cytodiagnosis | 1 | 2008 | 22 | 0.070 |
Why?
|
Chromosomes, Human, Pair 18 | 2 | 2001 | 64 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2008 | 712 | 0.070 |
Why?
|
Chromosome Deletion | 2 | 2008 | 663 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 486 | 0.070 |
Why?
|
DNA Repair Enzymes | 3 | 2003 | 48 | 0.070 |
Why?
|
Primary Health Care | 2 | 1992 | 793 | 0.070 |
Why?
|
Antigens, Nuclear | 1 | 2008 | 57 | 0.070 |
Why?
|
Intrauterine Devices | 1 | 1988 | 14 | 0.070 |
Why?
|
Cell Survival | 2 | 2008 | 892 | 0.070 |
Why?
|
Dysgerminoma | 2 | 1987 | 5 | 0.070 |
Why?
|
Hypothyroidism | 1 | 2009 | 100 | 0.070 |
Why?
|
Magnesium | 1 | 2008 | 127 | 0.070 |
Why?
|
Maternal Exposure | 1 | 2009 | 154 | 0.070 |
Why?
|
Urinary Bladder | 2 | 2006 | 251 | 0.070 |
Why?
|
Retinoids | 3 | 1997 | 32 | 0.070 |
Why?
|
Random Allocation | 2 | 2004 | 452 | 0.070 |
Why?
|
Pedigree | 2 | 2015 | 1693 | 0.070 |
Why?
|
Amino Acid Substitution | 2 | 2011 | 412 | 0.070 |
Why?
|
DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2007 | 13 | 0.070 |
Why?
|
Sputum | 1 | 2008 | 116 | 0.070 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2008 | 83 | 0.070 |
Why?
|
ADP Ribose Transferases | 1 | 2007 | 20 | 0.070 |
Why?
|
Pelvis | 1 | 1988 | 73 | 0.070 |
Why?
|
Colonic Neoplasms | 2 | 1992 | 271 | 0.070 |
Why?
|
Alkylation | 1 | 2007 | 10 | 0.070 |
Why?
|
Hepatitis C, Chronic | 2 | 2009 | 373 | 0.070 |
Why?
|
Biomarkers | 7 | 2005 | 3402 | 0.070 |
Why?
|
Sulfuric Acid Esters | 1 | 2007 | 9 | 0.070 |
Why?
|
Introns | 2 | 2006 | 313 | 0.070 |
Why?
|
Rad51 Recombinase | 1 | 2006 | 32 | 0.070 |
Why?
|
DNA, Mitochondrial | 1 | 2008 | 233 | 0.070 |
Why?
|
Genes, p16 | 2 | 2006 | 15 | 0.070 |
Why?
|
Cytosol | 1 | 2007 | 168 | 0.070 |
Why?
|
Fas Ligand Protein | 1 | 2006 | 39 | 0.070 |
Why?
|
Lymphocyte Activation | 2 | 2007 | 724 | 0.070 |
Why?
|
Pneumonia | 2 | 2013 | 340 | 0.070 |
Why?
|
Comparative Genomic Hybridization | 1 | 2008 | 577 | 0.060 |
Why?
|
Biological Assay | 1 | 2007 | 110 | 0.060 |
Why?
|
X-ray Repair Cross Complementing Protein 1 | 5 | 2007 | 24 | 0.060 |
Why?
|
G2 Phase | 2 | 2007 | 45 | 0.060 |
Why?
|
Luciferases | 2 | 2005 | 137 | 0.060 |
Why?
|
Telomere-Binding Proteins | 1 | 2006 | 46 | 0.060 |
Why?
|
Twins | 1 | 2006 | 74 | 0.060 |
Why?
|
Sex Ratio | 1 | 1986 | 13 | 0.060 |
Why?
|
Fruit | 3 | 2011 | 236 | 0.060 |
Why?
|
Lignans | 1 | 2005 | 6 | 0.060 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2006 | 46 | 0.060 |
Why?
|
Sex Characteristics | 2 | 2000 | 335 | 0.060 |
Why?
|
Comorbidity | 4 | 2012 | 1602 | 0.060 |
Why?
|
Liver Cirrhosis | 1 | 2013 | 933 | 0.060 |
Why?
|
Cell Death | 1 | 2006 | 249 | 0.060 |
Why?
|
Cell Division | 1 | 2007 | 772 | 0.060 |
Why?
|
Transients and Migrants | 2 | 2005 | 24 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 92 | 0.060 |
Why?
|
Aminobiphenyl Compounds | 1 | 2005 | 1 | 0.060 |
Why?
|
Esophageal Neoplasms | 2 | 2006 | 397 | 0.060 |
Why?
|
Ribonuclease, Pancreatic | 1 | 2005 | 22 | 0.060 |
Why?
|
Hodgkin Disease | 3 | 1998 | 301 | 0.060 |
Why?
|
Models, Biological | 1 | 2011 | 1533 | 0.060 |
Why?
|
Premenopause | 2 | 2002 | 38 | 0.060 |
Why?
|
ErbB Receptors | 1 | 2007 | 302 | 0.060 |
Why?
|
PTEN Phosphohydrolase | 3 | 2012 | 265 | 0.060 |
Why?
|
Genomics | 2 | 2011 | 1671 | 0.060 |
Why?
|
Enzyme Induction | 2 | 2007 | 105 | 0.060 |
Why?
|
Vegetables | 3 | 2011 | 274 | 0.060 |
Why?
|
Cadherins | 1 | 2006 | 184 | 0.060 |
Why?
|
Diet Surveys | 1 | 2005 | 103 | 0.060 |
Why?
|
Cultural Characteristics | 1 | 2005 | 42 | 0.060 |
Why?
|
Polymorphism, Single-Stranded Conformational | 2 | 2002 | 73 | 0.060 |
Why?
|
China | 4 | 2000 | 295 | 0.060 |
Why?
|
Structure-Activity Relationship | 1 | 2006 | 607 | 0.060 |
Why?
|
Medical History Taking | 3 | 2006 | 117 | 0.060 |
Why?
|
Radioimmunoassay | 2 | 2005 | 111 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2009 | 577 | 0.060 |
Why?
|
Cholecystectomy | 1 | 1985 | 65 | 0.060 |
Why?
|
Drosophila Proteins | 2 | 2002 | 761 | 0.060 |
Why?
|
Blotting, Southern | 2 | 2003 | 222 | 0.060 |
Why?
|
Bronchitis | 1 | 2005 | 34 | 0.060 |
Why?
|
Alternative Splicing | 1 | 2007 | 374 | 0.060 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2004 | 13 | 0.060 |
Why?
|
Stomach Neoplasms | 2 | 2001 | 561 | 0.060 |
Why?
|
Imidazoles | 1 | 2006 | 218 | 0.060 |
Why?
|
Genes | 1 | 2006 | 450 | 0.060 |
Why?
|
Feasibility Studies | 3 | 2013 | 817 | 0.060 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 158 | 0.060 |
Why?
|
Receptors, Calcitriol | 1 | 2005 | 74 | 0.060 |
Why?
|
Vitamin A | 2 | 2002 | 61 | 0.060 |
Why?
|
Energy Intake | 3 | 2011 | 519 | 0.060 |
Why?
|
Food | 1 | 2005 | 140 | 0.060 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2005 | 151 | 0.060 |
Why?
|
Radiotherapy Dosage | 1 | 2005 | 226 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2005 | 1314 | 0.060 |
Why?
|
Mothers | 1 | 2007 | 369 | 0.060 |
Why?
|
Oropharyngeal Neoplasms | 1 | 1988 | 283 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2003 | 835 | 0.060 |
Why?
|
Internship and Residency | 1 | 1995 | 1249 | 0.060 |
Why?
|
Sequence Analysis, DNA | 4 | 2015 | 1834 | 0.050 |
Why?
|
Vitamin E | 3 | 2001 | 69 | 0.050 |
Why?
|
Cell Line, Tumor | 5 | 2011 | 3719 | 0.050 |
Why?
|
Cytogenetic Analysis | 1 | 2004 | 82 | 0.050 |
Why?
|
Multifactorial Inheritance | 1 | 2004 | 158 | 0.050 |
Why?
|
Menopause | 1 | 2004 | 86 | 0.050 |
Why?
|
Xeroderma Pigmentosum Group A Protein | 1 | 2003 | 5 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2004 | 272 | 0.050 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 838 | 0.050 |
Why?
|
Psychology | 2 | 2015 | 62 | 0.050 |
Why?
|
MicroRNAs | 1 | 2010 | 948 | 0.050 |
Why?
|
Pharmacists | 1 | 2004 | 99 | 0.050 |
Why?
|
Oncogene Proteins, Viral | 1 | 2003 | 68 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2003 | 79 | 0.050 |
Why?
|
Education, Pharmacy | 1 | 2004 | 61 | 0.050 |
Why?
|
Clinical Trials as Topic | 4 | 2022 | 1150 | 0.050 |
Why?
|
Prostatectomy | 1 | 2004 | 357 | 0.050 |
Why?
|
Mouthwashes | 2 | 1994 | 13 | 0.050 |
Why?
|
Chromosome Disorders | 3 | 1996 | 315 | 0.050 |
Why?
|
Skin | 1 | 2005 | 554 | 0.050 |
Why?
|
NF-kappa B | 1 | 2005 | 486 | 0.050 |
Why?
|
DNA Ligases | 1 | 2002 | 17 | 0.050 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2003 | 109 | 0.050 |
Why?
|
Papillomaviridae | 2 | 1994 | 189 | 0.050 |
Why?
|
Arylsulfotransferase | 1 | 2002 | 6 | 0.050 |
Why?
|
Genetic Techniques | 1 | 2002 | 109 | 0.050 |
Why?
|
Counseling | 1 | 2004 | 239 | 0.050 |
Why?
|
Body Weight | 2 | 2011 | 1032 | 0.050 |
Why?
|
Barrett Esophagus | 1 | 2006 | 354 | 0.050 |
Why?
|
Marriage | 5 | 1989 | 33 | 0.050 |
Why?
|
Tea | 1 | 2002 | 19 | 0.050 |
Why?
|
Diet Records | 2 | 1999 | 76 | 0.050 |
Why?
|
Sulfotransferases | 1 | 2002 | 28 | 0.050 |
Why?
|
Hydrocarbons, Chlorinated | 1 | 2001 | 15 | 0.050 |
Why?
|
Agriculture | 1 | 2001 | 34 | 0.050 |
Why?
|
Medical Informatics | 1 | 2003 | 113 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2002 | 1666 | 0.050 |
Why?
|
Poly T | 1 | 2001 | 3 | 0.050 |
Why?
|
Endpoint Determination | 1 | 2001 | 59 | 0.050 |
Why?
|
Meta-Analysis as Topic | 2 | 2014 | 172 | 0.050 |
Why?
|
Alcohol Dehydrogenase | 1 | 2001 | 23 | 0.050 |
Why?
|
Insecticides | 1 | 2001 | 62 | 0.050 |
Why?
|
Genetic Testing | 3 | 2008 | 1085 | 0.050 |
Why?
|
Blood Preservation | 1 | 2001 | 32 | 0.050 |
Why?
|
Poly A | 1 | 2001 | 60 | 0.040 |
Why?
|
Gastroesophageal Reflux | 1 | 2004 | 337 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2004 | 433 | 0.040 |
Why?
|
Catechin | 1 | 2001 | 14 | 0.040 |
Why?
|
Computational Biology | 3 | 2014 | 885 | 0.040 |
Why?
|
Urban Population | 2 | 2005 | 240 | 0.040 |
Why?
|
Nutrition Assessment | 2 | 1999 | 139 | 0.040 |
Why?
|
Africa | 1 | 2021 | 142 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2011 | 82 | 0.040 |
Why?
|
Canada | 2 | 2013 | 343 | 0.040 |
Why?
|
Benzopyrenes | 1 | 2000 | 5 | 0.040 |
Why?
|
Plant Extracts | 1 | 2002 | 141 | 0.040 |
Why?
|
Early Diagnosis | 2 | 2013 | 198 | 0.040 |
Why?
|
Linear Models | 2 | 2012 | 724 | 0.040 |
Why?
|
United Kingdom | 2 | 2011 | 235 | 0.040 |
Why?
|
Lung | 2 | 2022 | 1558 | 0.040 |
Why?
|
Deoxyguanosine | 1 | 2000 | 13 | 0.040 |
Why?
|
Neuroblastoma | 1 | 1985 | 539 | 0.040 |
Why?
|
Point Mutation | 4 | 2003 | 360 | 0.040 |
Why?
|
Protein Kinases | 1 | 2001 | 342 | 0.040 |
Why?
|
Marijuana Smoking | 1 | 1999 | 33 | 0.040 |
Why?
|
Models, Genetic | 3 | 2010 | 789 | 0.040 |
Why?
|
Quality Control | 2 | 2010 | 129 | 0.040 |
Why?
|
Chromosomes, Human, Pair 7 | 2 | 1996 | 78 | 0.040 |
Why?
|
Poisson Distribution | 1 | 1999 | 53 | 0.040 |
Why?
|
Computer Simulation | 2 | 2012 | 701 | 0.040 |
Why?
|
Marijuana Abuse | 1 | 1999 | 54 | 0.040 |
Why?
|
Software Design | 1 | 1999 | 24 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 588 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2004 | 1326 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2015 | 619 | 0.040 |
Why?
|
Carcinogenicity Tests | 1 | 1998 | 22 | 0.040 |
Why?
|
Genes, bcl-1 | 1 | 1998 | 5 | 0.040 |
Why?
|
Benzo(a)pyrene | 1 | 1998 | 19 | 0.040 |
Why?
|
Transfection | 1 | 2000 | 1090 | 0.040 |
Why?
|
Testosterone | 2 | 2001 | 591 | 0.040 |
Why?
|
Cancer Care Facilities | 2 | 1988 | 39 | 0.040 |
Why?
|
Interphase | 1 | 1998 | 42 | 0.040 |
Why?
|
Genes, ras | 1 | 1998 | 101 | 0.040 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 458 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 1998 | 86 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2003 | 866 | 0.040 |
Why?
|
Chloride-Bicarbonate Antiporters | 1 | 1998 | 9 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 1998 | 77 | 0.040 |
Why?
|
RNA-Binding Proteins | 1 | 2022 | 607 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2012 | 141 | 0.040 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 2 | 2008 | 104 | 0.040 |
Why?
|
Teratogens | 1 | 1998 | 87 | 0.030 |
Why?
|
Down-Regulation | 2 | 2010 | 715 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2001 | 612 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2011 | 169 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2002 | 815 | 0.030 |
Why?
|
Quinone Reductases | 1 | 1997 | 4 | 0.030 |
Why?
|
Telomere Homeostasis | 1 | 2017 | 47 | 0.030 |
Why?
|
Mutation, Missense | 2 | 2015 | 923 | 0.030 |
Why?
|
Reference Standards | 2 | 2011 | 244 | 0.030 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 1996 | 80 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2007 | 72 | 0.030 |
Why?
|
Treatment Failure | 1 | 1998 | 360 | 0.030 |
Why?
|
Dietary Fiber | 1 | 1997 | 83 | 0.030 |
Why?
|
Mental Status Schedule | 1 | 2016 | 45 | 0.030 |
Why?
|
Telomeric Repeat Binding Protein 2 | 2 | 2006 | 7 | 0.030 |
Why?
|
Brazil | 1 | 2016 | 139 | 0.030 |
Why?
|
Y Chromosome | 1 | 1996 | 48 | 0.030 |
Why?
|
Genes, Modifier | 1 | 2016 | 17 | 0.030 |
Why?
|
Animals | 5 | 2005 | 36265 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2016 | 3058 | 0.030 |
Why?
|
Forestry | 1 | 1995 | 3 | 0.030 |
Why?
|
Child, Preschool | 6 | 2007 | 14748 | 0.030 |
Why?
|
Israel | 1 | 2015 | 48 | 0.030 |
Why?
|
Jews | 1 | 2015 | 34 | 0.030 |
Why?
|
Population Surveillance | 2 | 2016 | 417 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 1996 | 271 | 0.030 |
Why?
|
Administration, Oral | 1 | 1997 | 727 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 1996 | 292 | 0.030 |
Why?
|
X Chromosome | 1 | 1996 | 342 | 0.030 |
Why?
|
Korea | 2 | 2010 | 36 | 0.030 |
Why?
|
Genetic Linkage | 2 | 2008 | 480 | 0.030 |
Why?
|
Carcinoma, Basal Cell | 1 | 1995 | 74 | 0.030 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1995 | 123 | 0.030 |
Why?
|
Object Attachment | 1 | 2015 | 52 | 0.030 |
Why?
|
Asia | 1 | 2014 | 127 | 0.030 |
Why?
|
Coal | 1 | 1994 | 2 | 0.030 |
Why?
|
Vasectomy | 1 | 1994 | 17 | 0.030 |
Why?
|
Mining | 1 | 1994 | 8 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 1997 | 565 | 0.030 |
Why?
|
Chromosome Painting | 2 | 2004 | 18 | 0.030 |
Why?
|
Boston | 1 | 2014 | 121 | 0.030 |
Why?
|
Simplexvirus | 1 | 1994 | 106 | 0.030 |
Why?
|
North America | 1 | 2014 | 261 | 0.030 |
Why?
|
Cell Differentiation | 3 | 2008 | 2027 | 0.030 |
Why?
|
Occupational Diseases | 1 | 1994 | 75 | 0.030 |
Why?
|
Urogenital Neoplasms | 1 | 1993 | 16 | 0.030 |
Why?
|
Oxidative Stress | 2 | 2013 | 860 | 0.030 |
Why?
|
Activation, Metabolic | 1 | 2013 | 5 | 0.030 |
Why?
|
Infant | 5 | 1996 | 13107 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 34 | 0.030 |
Why?
|
Antimutagenic Agents | 1 | 1993 | 2 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 1993 | 47 | 0.030 |
Why?
|
Betaine | 1 | 2013 | 23 | 0.030 |
Why?
|
Internationality | 1 | 2013 | 137 | 0.030 |
Why?
|
Smoke-Free Policy | 1 | 2012 | 3 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2012 | 27 | 0.030 |
Why?
|
Choline | 1 | 2013 | 55 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2005 | 3204 | 0.020 |
Why?
|
Financing, Government | 1 | 2012 | 31 | 0.020 |
Why?
|
Air | 1 | 2012 | 26 | 0.020 |
Why?
|
Causality | 1 | 2012 | 93 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2011 | 1760 | 0.020 |
Why?
|
Physical Examination | 1 | 1993 | 163 | 0.020 |
Why?
|
Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2012 | 38 | 0.020 |
Why?
|
Research Support as Topic | 1 | 2012 | 66 | 0.020 |
Why?
|
Calibration | 1 | 2012 | 100 | 0.020 |
Why?
|
Cell Line, Transformed | 2 | 2002 | 170 | 0.020 |
Why?
|
Adolescent Development | 1 | 2012 | 34 | 0.020 |
Why?
|
raf Kinases | 1 | 2011 | 7 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 438 | 0.020 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2012 | 81 | 0.020 |
Why?
|
Platinum Compounds | 1 | 2011 | 6 | 0.020 |
Why?
|
Educational Measurement | 1 | 1995 | 337 | 0.020 |
Why?
|
Protein Transport | 1 | 2013 | 386 | 0.020 |
Why?
|
History, 21st Century | 1 | 2013 | 278 | 0.020 |
Why?
|
Food, Organic | 1 | 2011 | 3 | 0.020 |
Why?
|
Receptors, Cholinergic | 1 | 2012 | 85 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2013 | 198 | 0.020 |
Why?
|
Single Parent | 1 | 2011 | 1 | 0.020 |
Why?
|
Diet, Fat-Restricted | 1 | 2011 | 41 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 1994 | 200 | 0.020 |
Why?
|
DNA, Viral | 1 | 1993 | 497 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2011 | 34 | 0.020 |
Why?
|
Gene Expression | 3 | 2002 | 1614 | 0.020 |
Why?
|
Poly-ADP-Ribose Binding Proteins | 2 | 2002 | 32 | 0.020 |
Why?
|
Retinoid X Receptor alpha | 1 | 2011 | 20 | 0.020 |
Why?
|
Specialization | 1 | 1992 | 82 | 0.020 |
Why?
|
Siblings | 1 | 2012 | 198 | 0.020 |
Why?
|
Ki-1 Antigen | 1 | 2011 | 29 | 0.020 |
Why?
|
Hair Dyes | 1 | 1990 | 2 | 0.020 |
Why?
|
Meiosis | 1 | 1991 | 115 | 0.020 |
Why?
|
Mammography | 1 | 1992 | 134 | 0.020 |
Why?
|
Television | 1 | 2011 | 72 | 0.020 |
Why?
|
Drug Synergism | 1 | 1991 | 239 | 0.020 |
Why?
|
Sports | 1 | 2011 | 69 | 0.020 |
Why?
|
Gonorrhea | 1 | 1991 | 40 | 0.020 |
Why?
|
Singapore | 1 | 2010 | 17 | 0.020 |
Why?
|
Oxidants | 1 | 2010 | 34 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 179 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 1148 | 0.020 |
Why?
|
Twin Studies as Topic | 1 | 2010 | 15 | 0.020 |
Why?
|
Medicine | 1 | 1992 | 107 | 0.020 |
Why?
|
Sexual Partners | 1 | 1991 | 87 | 0.020 |
Why?
|
Cytoplasm | 1 | 2011 | 303 | 0.020 |
Why?
|
Karyopherins | 1 | 2010 | 37 | 0.020 |
Why?
|
Guanine | 1 | 2010 | 63 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1996 | 567 | 0.020 |
Why?
|
Pesticides | 1 | 2010 | 31 | 0.020 |
Why?
|
Tumor Burden | 1 | 2011 | 258 | 0.020 |
Why?
|
Contraception | 1 | 1991 | 60 | 0.020 |
Why?
|
Self Report | 1 | 2013 | 551 | 0.020 |
Why?
|
Massachusetts | 1 | 2010 | 131 | 0.020 |
Why?
|
Tars | 1 | 1990 | 1 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 2013 | 377 | 0.020 |
Why?
|
Radiation, Nonionizing | 1 | 1989 | 1 | 0.020 |
Why?
|
Income | 1 | 1991 | 141 | 0.020 |
Why?
|
Carboplatin | 1 | 2010 | 87 | 0.020 |
Why?
|
Equipment Safety | 1 | 1989 | 37 | 0.020 |
Why?
|
Japan | 1 | 2010 | 156 | 0.020 |
Why?
|
MutL Protein Homolog 1 | 2 | 2001 | 54 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 129 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2011 | 195 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2011 | 399 | 0.020 |
Why?
|
Radiotherapy | 1 | 1990 | 151 | 0.020 |
Why?
|
Microsatellite Repeats | 2 | 2001 | 239 | 0.020 |
Why?
|
International Cooperation | 1 | 2010 | 166 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2010 | 160 | 0.020 |
Why?
|
Actins | 2 | 2003 | 353 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2010 | 142 | 0.020 |
Why?
|
Curriculum | 1 | 1995 | 775 | 0.020 |
Why?
|
Xeroderma Pigmentosum | 2 | 2001 | 7 | 0.020 |
Why?
|
Information Dissemination | 1 | 2011 | 196 | 0.020 |
Why?
|
Blotting, Western | 1 | 2011 | 1138 | 0.020 |
Why?
|
HeLa Cells | 1 | 2011 | 827 | 0.020 |
Why?
|
Plant Preparations | 2 | 1999 | 18 | 0.020 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2010 | 207 | 0.020 |
Why?
|
Proto-Oncogenes | 1 | 2008 | 34 | 0.020 |
Why?
|
beta-Tocopherol | 1 | 2008 | 1 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1831 | 0.020 |
Why?
|
gamma-Tocopherol | 1 | 2008 | 4 | 0.020 |
Why?
|
Software Validation | 1 | 1988 | 11 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2011 | 688 | 0.020 |
Why?
|
alpha-Tocopherol | 1 | 2008 | 38 | 0.020 |
Why?
|
Ku Autoantigen | 1 | 2008 | 22 | 0.020 |
Why?
|
Sampling Studies | 1 | 1988 | 78 | 0.020 |
Why?
|
Internet | 1 | 2011 | 393 | 0.020 |
Why?
|
Patient Compliance | 1 | 1992 | 480 | 0.020 |
Why?
|
DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 26 | 0.020 |
Why?
|
Overweight | 1 | 2011 | 383 | 0.020 |
Why?
|
Homosexuality | 1 | 1988 | 18 | 0.020 |
Why?
|
Hepatitis B, Chronic | 1 | 2009 | 83 | 0.020 |
Why?
|
Bronchi | 1 | 2008 | 106 | 0.020 |
Why?
|
Thyroid Nuclear Factor 1 | 1 | 2007 | 15 | 0.020 |
Why?
|
Tissue Adhesions | 1 | 1988 | 31 | 0.020 |
Why?
|
Nitrites | 1 | 1988 | 51 | 0.020 |
Why?
|
Anti-Infective Agents | 1 | 2010 | 269 | 0.020 |
Why?
|
Catalytic Domain | 1 | 2008 | 172 | 0.020 |
Why?
|
Twins, Dizygotic | 1 | 2007 | 47 | 0.020 |
Why?
|
Transglutaminases | 1 | 2007 | 27 | 0.020 |
Why?
|
Cysteine Endopeptidases | 1 | 2008 | 119 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2009 | 207 | 0.020 |
Why?
|
Motivation | 1 | 1990 | 331 | 0.020 |
Why?
|
Cognition | 1 | 2013 | 815 | 0.020 |
Why?
|
Genes, erbB-1 | 1 | 2007 | 10 | 0.020 |
Why?
|
S Phase | 1 | 2007 | 78 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2007 | 102 | 0.020 |
Why?
|
Drug Interactions | 1 | 2008 | 261 | 0.020 |
Why?
|
Valine | 1 | 2007 | 116 | 0.020 |
Why?
|
Radiation Effects | 1 | 2006 | 14 | 0.020 |
Why?
|
Guanosine | 1 | 2006 | 12 | 0.020 |
Why?
|
Twins, Monozygotic | 1 | 2007 | 122 | 0.020 |
Why?
|
Telomeric Repeat Binding Protein 1 | 1 | 2006 | 3 | 0.020 |
Why?
|
Thymidine | 1 | 2006 | 55 | 0.020 |
Why?
|
Aurora Kinases | 1 | 2006 | 28 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2007 | 194 | 0.020 |
Why?
|
Cryptorchidism | 1 | 1986 | 38 | 0.020 |
Why?
|
rap1 GTP-Binding Proteins | 1 | 2006 | 18 | 0.020 |
Why?
|
Genes, Neoplasm | 1 | 2006 | 90 | 0.020 |
Why?
|
Aurora Kinase A | 1 | 2006 | 38 | 0.020 |
Why?
|
Sarcoma, Kaposi | 1 | 1988 | 137 | 0.020 |
Why?
|
Sunburn | 1 | 2005 | 5 | 0.020 |
Why?
|
Social Support | 1 | 2009 | 380 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1069 | 0.020 |
Why?
|
Aneuploidy | 1 | 2006 | 145 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2006 | 2658 | 0.020 |
Why?
|
RNA Interference | 1 | 2007 | 544 | 0.020 |
Why?
|
Karyotyping | 2 | 1996 | 324 | 0.020 |
Why?
|
No-Observed-Adverse-Effect Level | 1 | 2005 | 5 | 0.020 |
Why?
|
Electromagnetic Fields | 1 | 1985 | 28 | 0.020 |
Why?
|
Teratoma | 1 | 1986 | 130 | 0.020 |
Why?
|
Recurrence | 1 | 2009 | 1464 | 0.020 |
Why?
|
Electronics | 1 | 1985 | 47 | 0.010 |
Why?
|
Restriction Mapping | 1 | 2005 | 192 | 0.010 |
Why?
|
Receptors, Retinoic Acid | 1 | 2005 | 98 | 0.010 |
Why?
|
Cryptoxanthins | 1 | 2005 | 2 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 90 | 0.010 |
Why?
|
Xanthophylls | 1 | 2005 | 4 | 0.010 |
Why?
|
Cytochrome P-450 CYP1B1 | 1 | 2005 | 30 | 0.010 |
Why?
|
Zeaxanthins | 1 | 2005 | 9 | 0.010 |
Why?
|
Infant, Newborn | 2 | 1996 | 8560 | 0.010 |
Why?
|
Lutein | 1 | 2005 | 15 | 0.010 |
Why?
|
Isomerism | 1 | 2005 | 30 | 0.010 |
Why?
|
Food Analysis | 1 | 2005 | 28 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2005 | 147 | 0.010 |
Why?
|
Calcitriol | 1 | 2005 | 81 | 0.010 |
Why?
|
Iron | 1 | 2007 | 303 | 0.010 |
Why?
|
Molecular Biology | 1 | 2005 | 80 | 0.010 |
Why?
|
Chromosome Segregation | 1 | 2004 | 67 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 1988 | 447 | 0.010 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2006 | 374 | 0.010 |
Why?
|
Palliative Care | 1 | 2008 | 451 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2008 | 666 | 0.010 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2005 | 198 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 62 | 0.010 |
Why?
|
Weight Gain | 1 | 2007 | 413 | 0.010 |
Why?
|
Infertility, Male | 1 | 1987 | 287 | 0.010 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2004 | 60 | 0.010 |
Why?
|
Geography | 1 | 2004 | 124 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2006 | 387 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 363 | 0.010 |
Why?
|
Binding Sites | 1 | 2006 | 1365 | 0.010 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2003 | 24 | 0.010 |
Why?
|
Mastectomy, Segmental | 1 | 2003 | 40 | 0.010 |
Why?
|
Oropharynx | 1 | 2003 | 39 | 0.010 |
Why?
|
Professional-Patient Relations | 1 | 2004 | 89 | 0.010 |
Why?
|
DNA-Formamidopyrimidine Glycosylase | 1 | 2003 | 1 | 0.010 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 11 | 0.010 |
Why?
|
N-Glycosyl Hydrolases | 1 | 2003 | 14 | 0.010 |
Why?
|
Papanicolaou Test | 1 | 2003 | 36 | 0.010 |
Why?
|
Medically Underserved Area | 1 | 2004 | 94 | 0.010 |
Why?
|
Vaginal Smears | 1 | 2003 | 52 | 0.010 |
Why?
|
Sunlight | 1 | 2003 | 25 | 0.010 |
Why?
|
Chloramphenicol | 1 | 2002 | 28 | 0.010 |
Why?
|
DNA Ligase ATP | 1 | 2002 | 12 | 0.010 |
Why?
|
Calcium | 1 | 2007 | 1145 | 0.010 |
Why?
|
Hand Disinfection | 1 | 2001 | 18 | 0.010 |
Why?
|
Hygiene | 1 | 2001 | 27 | 0.010 |
Why?
|
Cardia | 1 | 2001 | 27 | 0.010 |
Why?
|
Base Pair Mismatch | 1 | 2001 | 22 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 1 | 2001 | 40 | 0.010 |
Why?
|
Dihydrotestosterone | 1 | 2001 | 71 | 0.010 |
Why?
|
Smad2 Protein | 1 | 2001 | 52 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2001 | 125 | 0.010 |
Why?
|
Gonadal Steroid Hormones | 1 | 2001 | 98 | 0.010 |
Why?
|
Blood Specimen Collection | 1 | 2001 | 48 | 0.010 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2000 | 50 | 0.010 |
Why?
|
Cryopreservation | 1 | 2001 | 75 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2001 | 159 | 0.010 |
Why?
|
Gene Silencing | 1 | 2001 | 251 | 0.010 |
Why?
|
Radiation Tolerance | 1 | 2000 | 60 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2003 | 821 | 0.010 |
Why?
|
Demography | 1 | 2000 | 246 | 0.010 |
Why?
|
Awards and Prizes | 1 | 2000 | 70 | 0.010 |
Why?
|
Stigmasterol | 1 | 1999 | 3 | 0.010 |
Why?
|
Patient Care Planning | 1 | 2000 | 132 | 0.010 |
Why?
|
Genistein | 1 | 1999 | 40 | 0.010 |
Why?
|
Alcoholism | 1 | 2001 | 247 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 713 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2000 | 676 | 0.010 |
Why?
|
Trans-Activators | 1 | 2001 | 827 | 0.010 |
Why?
|
Metaphase | 1 | 1996 | 35 | 0.010 |
Why?
|
Ataxia Telangiectasia | 1 | 1996 | 16 | 0.010 |
Why?
|
Base Composition | 1 | 1995 | 75 | 0.010 |
Why?
|
Cholesterol | 1 | 1999 | 574 | 0.010 |
Why?
|
Environmental Pollutants | 1 | 1996 | 79 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1988 | 244 | 0.010 |
Why?
|
New England | 1 | 1995 | 13 | 0.010 |
Why?
|
Smoke | 1 | 1995 | 67 | 0.010 |
Why?
|
Bias | 1 | 1996 | 147 | 0.010 |
Why?
|
Drug Resistance | 1 | 1996 | 263 | 0.010 |
Why?
|
Observer Variation | 1 | 1996 | 313 | 0.010 |
Why?
|
Bone Marrow | 1 | 1996 | 334 | 0.010 |
Why?
|
Prostatic Diseases | 1 | 1994 | 15 | 0.010 |
Why?
|
Leukemia, Radiation-Induced | 1 | 1994 | 3 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 1993 | 54 | 0.010 |
Why?
|
Genes, Viral | 1 | 1993 | 186 | 0.010 |
Why?
|
Genome | 1 | 1995 | 525 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 1993 | 397 | 0.010 |
Why?
|
Parity | 1 | 1992 | 84 | 0.010 |
Why?
|
Acetylcysteine | 1 | 1993 | 85 | 0.010 |
Why?
|
Epithelium | 1 | 1993 | 370 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 1993 | 455 | 0.010 |
Why?
|
Cause of Death | 1 | 1994 | 499 | 0.010 |
Why?
|
Helicobacter Infections | 1 | 2000 | 1273 | 0.010 |
Why?
|
Nitroso Compounds | 1 | 1988 | 8 | 0.000 |
Why?
|
Aphrodisiacs | 1 | 1988 | 5 | 0.000 |
Why?
|
Death Certificates | 1 | 1987 | 11 | 0.000 |
Why?
|
Hydrocarbons | 1 | 1987 | 9 | 0.000 |
Why?
|
Single Person | 1 | 1987 | 1 | 0.000 |
Why?
|
Divorce | 1 | 1987 | 7 | 0.000 |
Why?
|
Opportunistic Infections | 1 | 1988 | 79 | 0.000 |
Why?
|
Administration, Inhalation | 1 | 1988 | 189 | 0.000 |
Why?
|
Acute Disease | 1 | 1989 | 1184 | 0.000 |
Why?
|